Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Rare Diseases

Prostatic Neoplasms

Carcinoma, Renal Cell

Kidney Neoplasms

Carcinoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Atezolizumab

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

100 mg orally twice daily for the first 14 days of each 28-day cycle.

Ciforadenant

100 mg orally twice daily for 28 days of each 28-day cycle.

200 mg orally once daily for the first 14 days of each 28-day cycle.

Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.

Ciforadenant + atezolizumab

Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.

Mehrdad Mobasher, MD, MPH

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Genentech, Inc.

Corvus Pharmaceuticals, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for ciforadenant + atezolizumab